Notizia - Recent Pharma, Healthcare and Biotech Happenings

Iovance infuses USD 75 M to boost Cancer therapy Iovance Biotherapeutics is all set to build a 136,000-square-foot facility in Philadelphia to develop cancer therapies using its tumour-infiltrating lymphocyte (TIL) technology. Building the new facility will cost the Iovance around USD 75 Million. The biotherapeutic company is looking to reduce its reliance on contract manufacturing organizations while climbing higher in the market with its leading cancer immunotherapy, lifileucel. The tumour-infiltrating lymphocyte facility will benefit several thousand patients a year. Novartis pumps USD 30 M into Ayala Pharmaceuticals Israel-based Ayala Pharmaceuticals ha...